{"id":153084,"date":"2013-06-19T00:00:00","date_gmt":"2013-06-19T00:00:00","guid":{"rendered":"https:\/\/v2.optiknow.ca\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/"},"modified":"2013-06-19T00:00:00","modified_gmt":"2013-06-19T00:00:00","slug":"espoir-dans-le-traitement-du-melanome-uveal-metastatique","status":"publish","type":"post","link":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/","title":{"rendered":"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique"},"content":{"rendered":"<p>Pour la premi\u00e8re fois, un m\u00e9dicament d\u00e9montre un r\u00e9el impact b\u00e9n\u00e9fique pour des patients atteints d'un m\u00e9lanome uv\u00e9al m\u00e9tastatique, une maladie souvent qualifi\u00e9e d'\u00ab\u00a0intraitable\u00a0\u00bb.<\/p>\n<p>\u00a0<\/p>\n<p>La bonne nouvelle est venue du Memorial Sloan-Kettering Cancer Center, dont les r\u00e9sultats de recherche ont \u00e9t\u00e9 pr\u00e9sent\u00e9s \u00e0 la 49<sup>e<\/sup> rencontre annuelle de l'American Society of Clinical Oncology. Les chercheurs ont d\u00e9montr\u00e9 que les patients trait\u00e9s au s\u00e9lum\u00e9tinib avaient une survie sans progression de la tumeur de 16 semaines, alors que la moiti\u00e9 des patients voyaient la taille de leur tumeur diminuer, et 15 % la voyaient diminuer de mani\u00e8re tr\u00e8s significative.<\/p>\n<p>\u00a0<\/p>\n<p>En comparaison, les patients trait\u00e9s au t\u00e9mozolomide, la chimioth\u00e9rapie standard, avaient une survie sans progression de sept semaines, sans qu'aucun ne voie la taille de sa tumeur diminuer. De plus, le s\u00e9lum\u00e9tinib allongeait la survie totale de 10,8 mois, contre 9,4 mois avec le t\u00e9mozolomide.<\/p>\n<p>\u00a0<\/p>\n<p>\u00ab\u00a0Il s'agit de la premi\u00e8re \u00e9tude \u00e0 d\u00e9montrer qu'une th\u00e9rapie syst\u00e9mique peut apporter un avantage clinique significatif aux patients atteints de la forme avanc\u00e9e du m\u00e9lanome uv\u00e9al\u00a0\u00bb, explique le chercheur principal Richard D. Carvajal.<\/p>\n<p><\/p>\n<p>Source\u00a0: <a title=\"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique   \" href=\"http:\/\/www.mskcc.org\/pressroom\/press\/new-therapy-shown-improve-progression-free-survival-and-shrink-tumors-rare-first-time\">http:\/\/www.mskcc.org\/pressroom\/press\/new-therapy-shown-improve-progression-free-survival-and-shrink-tumors-rare-first-time<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pour la premi\u00e8re fois, un m\u00e9dicament d\u00e9montre un r\u00e9el impact b\u00e9n\u00e9fique pour des patients atteints d'un m\u00e9lanome uv\u00e9al m\u00e9tastatique, une maladie souvent qualifi\u00e9e d'\u00ab\u00a0intraitable\u00a0\u00bb. \u00a0 La bonne nouvelle est venue [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23133],"tags":[],"class_list":["post-153084","post","type-post","status-publish","format-standard","hentry","category-nouvelles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique - OptikNow<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique - OptikNow\" \/>\n<meta property=\"og:description\" content=\"Pour la premi\u00e8re fois, un m\u00e9dicament d\u00e9montre un r\u00e9el impact b\u00e9n\u00e9fique pour des patients atteints d&#039;un m\u00e9lanome uv\u00e9al m\u00e9tastatique, une maladie souvent qualifi\u00e9e d&#039;\u00ab\u00a0intraitable\u00a0\u00bb. \u00a0 La bonne nouvelle est venue [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/\" \/>\n<meta property=\"og:site_name\" content=\"OptikNow\" \/>\n<meta property=\"article:published_time\" content=\"2013-06-19T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Optiknow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Optiknow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/\"},\"author\":{\"name\":\"Optiknow\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\"},\"headline\":\"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique\",\"datePublished\":\"2013-06-19T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/\"},\"wordCount\":226,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/\",\"name\":\"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique - OptikNow\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\"},\"datePublished\":\"2013-06-19T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2013\\\/06\\\/19\\\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"name\":\"OptikNow\",\"description\":\"Canadian Eye Care and Eyewear News for Eye Care Professionals\",\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\",\"name\":\"OptikNow\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"contentUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"width\":1181,\"height\":250,\"caption\":\"OptikNow\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\",\"name\":\"Optiknow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"caption\":\"Optiknow\"},\"sameAs\":[\"https:\\\/\\\/v2.optiknow.ca\"],\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/author\\\/optiknow\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique - OptikNow","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique - OptikNow","og_description":"Pour la premi\u00e8re fois, un m\u00e9dicament d\u00e9montre un r\u00e9el impact b\u00e9n\u00e9fique pour des patients atteints d'un m\u00e9lanome uv\u00e9al m\u00e9tastatique, une maladie souvent qualifi\u00e9e d'\u00ab\u00a0intraitable\u00a0\u00bb. \u00a0 La bonne nouvelle est venue [&hellip;]","og_url":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/","og_site_name":"OptikNow","article_published_time":"2013-06-19T00:00:00+00:00","author":"Optiknow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Optiknow","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/#article","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/"},"author":{"name":"Optiknow","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150"},"headline":"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique","datePublished":"2013-06-19T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/"},"wordCount":226,"commentCount":0,"publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"articleSection":["Nouvelles"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/","url":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/","name":"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique - OptikNow","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#website"},"datePublished":"2013-06-19T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/v2.optiknow.ca\/fr\/2013\/06\/19\/espoir-dans-le-traitement-du-melanome-uveal-metastatique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/v2.optiknow.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Espoir dans le traitement du m\u00e9lanome uv\u00e9al m\u00e9tastatique"}]},{"@type":"WebSite","@id":"https:\/\/v2.optiknow.ca\/fr\/#website","url":"https:\/\/v2.optiknow.ca\/fr\/","name":"OptikNow","description":"Canadian Eye Care and Eyewear News for Eye Care Professionals","publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/v2.optiknow.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/v2.optiknow.ca\/fr\/#organization","name":"OptikNow","url":"https:\/\/v2.optiknow.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","contentUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","width":1181,"height":250,"caption":"OptikNow"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150","name":"Optiknow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","caption":"Optiknow"},"sameAs":["https:\/\/v2.optiknow.ca"],"url":"https:\/\/v2.optiknow.ca\/fr\/author\/optiknow\/"}]}},"_links":{"self":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/comments?post=153084"}],"version-history":[{"count":0,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153084\/revisions"}],"wp:attachment":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/media?parent=153084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/categories?post=153084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/tags?post=153084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}